Literature DB >> 3288033

Diagnostic heterogeneity in clinical trials for congestive heart failure.

P R Marantz1, M H Alderman, J N Tobin.   

Abstract

There are no uniform diagnostic criteria for congestive heart failure. To determine the pattern of diagnostic criteria used, reports of 51 randomized, double-blind, placebo-controlled, clinical drug trials published between 1977 and 1985 were reviewed. Only 23 (45%) of the trials specified objective diagnostic criteria beyond treatment history, clinical diagnosis, or functional class. Of these, there were two trials each for digoxin, hydralazine, amrinone, and metoprolol; for each pair, only one study showed therapy beneficial. Of the amrinone pair, the positive study required a lower ejection fraction (less than 30% compared with less than 45%) and selected patients with more clinical severity. Conversely, for metoprolol, the positive study specified a higher ejection fraction (less than 49% compared with less than 35%) and selected patients with clinically milder disease, suggesting that conflicting results may relate to differences in study population. Many studies of congestive heart failure are done without explicit diagnostic criteria. Criteria lack uniformity, and such discrepancies may explain conflicting results.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288033     DOI: 10.7326/0003-4819-109-1-55

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Classification of heart failure in population based research: an assessment of six heart failure scores.

Authors:  A Mosterd; J W Deckers; A W Hoes; A Nederpel; A Smeets; D T Linker; D E Grobbee
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

Review 2.  Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks.

Authors:  U Ravens; M Wehr
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 3.  Hypertension, hypertrophy, heart failure.

Authors:  M G Nicholls
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure.

Authors:  Mark E Pepin; Stavros Drakos; Chae-Myeong Ha; Martin Tristani-Firouzi; Craig H Selzman; James C Fang; Adam R Wende; Omar Wever-Pinzon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-07-12       Impact factor: 4.733

Review 5.  Diagnosis of patients with chronic heart failure in primary care: usefulness of history, examination, and investigations.

Authors:  K Khunti; R Baker; G Grimshaw
Journal:  Br J Gen Pract       Date:  2000-01       Impact factor: 5.386

Review 6.  The heart failure epidemic.

Authors:  Véronique L Roger
Journal:  Int J Environ Res Public Health       Date:  2010-04-19       Impact factor: 3.390

Review 7.  Risks and benefits of the treatment of heart failure. Current status.

Authors:  J F Moran
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 8.  Epidemiology of heart failure.

Authors:  Véronique L Roger
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

9.  Prevalence of heart failure in three general practices in north west London.

Authors:  J Parameshwar; M M Shackell; A Richardson; P A Poole-Wilson; G C Sutton
Journal:  Br J Gen Pract       Date:  1992-07       Impact factor: 5.386

Review 10.  The management of heart failure: a matter of definition?

Authors:  A Harley
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.